ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office
24 Janeiro 2024 - 10:30AM
ELEVAI LABS, INC., (NASDAQ: ELAB) a medical aesthetic company
specializing in physician-dispensed skincare, is pleased to
announce today that the United States Patent & Trademark Office
(USPTO) issued US Patent No. 11,878,038, entitled “Exosome-based
Skincare Product” (the “Patent”) covering the primary formulation
for ELEVAI’s exosome-based skin care products. The ELEVAI
exosomes™ used in ELEVAI Labs’ formulations are derived from
specially cultured and treated umbilical mesenchymal stem cells to
generate a specific profile for the applications desired. ELEVAI’s
enfinity™ and empower™ formulations are both covered by the Patent.
“We are pleased the USPTO has issued this
critical patent, which is the first step towards building ELEVAI’s
patent moat in the aesthetics market. The Company will continue to
strive to invent or acquire the best and most technically advanced
products, which we believe will maintain ELEVAI’s competitive edge
in the physician-dispensed skincare market and beyond,” said ELEVAI
co-founder and CEO, Jordan R. Plews, PhD.
About ELEVAI Labs
ELEVAI Labs, Inc. (NASDAQ: ELAB) is a medical
aesthetics company developing cutting-edge physician-dispensed skin
care applications. The company solves unmet needs in the medical
aesthetics space through a combination of cutting-edge
science-driven and next-generation consumer applications. ELEVAI
Labs develops topical aesthetic skin care cosmetic products for the
physician-dispensed market, with a focus on leveraging a
proprietary stem cell exosome technology. For more information
visit www.elevaiskincare.com.
Forward-Looking Statements
Certain statements made in this press release
are "forward-looking statements'' within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified using words
such as "anticipate", "believe", "expect", "estimate", "plan",
"outlook", and "project" and other similar expressions that predict
or indicate future events or trends or that are not statements of
historical matters. These forward-looking statements reflect the
current analysis of existing information and are subject to various
risks and uncertainties. As a result, caution must be exercised in
relying on forward-looking statements. Due to known and unknown
risks, actual results may differ materially from the Company’s
expectations or projections. The following factors, among others,
could cause actual results to differ materially from those
described in these forward-looking statements: (i) the failure to
meet projected research & development and production targets;
(ii) changes in applicable laws or regulations; and (iii) other
risks and uncertainties described herein, as well as those risks
and uncertainties discussed from time to time in other reports and
other public filings with the Securities and Exchange Commission
(the "SEC"). These statements are subject to uncertainties and
risks including, but not limited to, the uncertainties related to
market conditions and the completion of the initial public offering
on the anticipated terms or at all, and other factors discussed in
the “Risk Factors” section of the registration statement filed with
the SEC. The Company’s SEC filings are available publicly on the
SEC’s website at www.sec.gov. Any forward-looking statement made by
us in this press release is based only on information currently
available to the Company and speaks only as of the date on which it
is made. The Company undertakes no obligation to publicly update
any forward-looking statement, whether written or oral, that may be
made from time to time, whether because of new information, future
developments, or otherwise, except as required by law.
Media ContactBrenda BuechlerChief Marketing
Officercontact@elevailabs.com
Investor RelationsIR@elevailabs.com
Elevai Labs (NASDAQ:ELAB)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Elevai Labs (NASDAQ:ELAB)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024